GLP-1 medications have changed the way we approach weight management and metabolic health. But as a physician focused on women's health, prevention and longevity, I believe the conversation should extend beyond the number on the scale.
We need to ask a bigger question: Can we improve metabolic health, protect cardiovascular function and support healthy aging without necessarily pursuing maximal weight loss? This is where the discussion around GLP-1 microdosing comes in.
Microdosing generally refers to using doses below the usual therapeutic maintenance range or remaining at a low starting dose for longer than the standard dose-escalation schedule. The goal is often to find the lowest dose that is appropriate for an individual's clinical needs while limiting side effects and avoiding unnecessary weight loss.
It is an intriguing concept. However, we need to distinguish what we know about GLP-1 medications overall from what has actually been demonstrated about microdosing specifically.
Cardiovascular disease remains a leading cause of death in women, and risk can accumulate silently for decades before a heart attack or stroke occurs.
Excess visceral fat, insulin resistance, elevated blood pressure, abnormal cholesterol and chronic metabolic dysfunction all contribute to cardiovascular risk.
GLP-1 medications can improve several of these risk factors. Depending on the medication and the patient, benefits may include weight reduction, improved glucose regulation, lower blood pressure and improvements in certain lipid measures.
Importantly, clinical trials have also demonstrated cardiovascular benefits with specific GLP-1 medications in selected high-risk populations. For example, semaglutide has been shown to reduce major cardiovascular events in certain adults with overweight or obesity and established cardiovascular disease, even without diabetes.
Here is the distinction: those cardiovascular outcome results cannot automatically be applied to microdoses. We do not yet have definitive clinical trial evidence that staying at a very low dose provides the same protection against heart attack or stroke.
The goal should not simply be to prescribe less medication. It should be to identify an appropriate, evidence-based treatment strategy for the individual patient.
The brain is metabolically active and depends on healthy blood vessels, adequate energy supply and effective glucose regulation.
Insulin resistance, diabetes, hypertension and vascular disease are associated with an increased risk of cognitive decline. Improving these conditions is an important part of protecting long-term brain health.
GLP-1 receptors and related signaling pathways have attracted considerable research interest because of their potential effects on inflammation, cellular stress and processes involved in neurological health.
There is growing scientific interest in whether GLP-1 medications could eventually have a role in preventing or treating certain neurodegenerative diseases. However, the evidence remains incomplete, and these medications are not established treatments for preventing Alzheimer's disease or cognitive decline in otherwise healthy individuals. We also cannot conclude that microdosing produces a direct neuroprotective effect.
What we can do today is focus on the factors that support brain health: maintaining healthy blood pressure and glucose levels, exercising regularly, protecting sleep, preserving muscle mass and addressing cardiovascular risk early.
Chronic, low-grade inflammation is increasingly recognized as a component of metabolic dysfunction and many age-related diseases.
Visceral fat is not simply stored energy. It is metabolically active tissue that releases signaling molecules involved in inflammatory processes. When visceral fat accumulates alongside insulin resistance, the body's inflammatory environment can become less favorable.
Studies of GLP-1-based treatments have reported reductions in certain inflammatory markers, including high-sensitivity C-reactive protein (hs-CRP). These changes may reflect a combination of weight loss, improved metabolic function and other biological effects.
Tirzepatide, which acts on both GIP and GLP-1 receptors, has also demonstrated improvements in inflammatory biomarkers in clinical research.
The important question is whether these benefits occur at doses lower than those studied in established treatment protocols, and whether they translate into fewer long-term complications.
That remains an area for further research. A reduction in an inflammatory marker is encouraging, but it does not automatically prove that a treatment prevents every disease associated with inflammation.
In clinical practice, patients are not interchangeable. Two women with the same weight may have very different metabolic profiles, cardiovascular risks, body compositions and treatment goals.
One patient may need substantial weight loss to improve obesity-related complications. Another may be closer to her target weight but struggle with insulin resistance or other metabolic risk factors. A third may experience significant gastrointestinal side effects during dose escalation. This is why treatment should be individualized.
For some patients, a clinician may consider a slower titration or a longer period at a lower dose, depending on the medication, indication, response and tolerability. The appropriate dose must still be guided by clinical evidence and the medication's prescribing information.
However, a lower dose is not automatically safer or more effective, and we do not yet know whether microdosing offers the same long-term cardiovascular or other health benefits demonstrated with studied regimens.
There is also a critical consideration that often gets overlooked: preserving muscle is part of longevity.
When weight loss is excessive or rapid, lean tissue can be lost along with fat. Muscle is essential for strength, glucose disposal, physical independence and resilience as we age.
For women in particular, a longevity-focused plan should consider adequate protein intake, resistance training, sufficient nutrition and appropriate monitoring of body composition, not just weight.
GLP-1 medications represent an important advance in metabolic medicine. Their potential relevance to cardiovascular health, inflammatory pathways and neurological research makes this an exciting area of science.
But we should not confuse promising research with proven outcomes. The strongest evidence supports specific medications at studied doses in defined patient populations. The long-term benefits of microdosing for heart health, brain health and inflammation still need to be established.
My approach to longevity medicine is to look at the whole picture: metabolic markers, cardiovascular risk, body composition, muscle strength, hormonal health, sleep, nutrition and lifestyle.
The objective is not to make a patient as small as possible. It is to help her remain metabolically healthy, physically strong and independent for as long as possible.
Longevity is not simply about living longer. It is about preserving the health and function that allow us to live well.
Medical note: GLP-1 medications require individualized medical assessment. Do not change your dose or dosing schedule without discussing it with your prescribing clinician. Compounded products can introduce additional dosing and quality concerns.
— Dr. Shamsah Amersi, MD, FACOG
Women's Health | Preventive Medicine | Longevity & Healthspan
